Digital Mammography Firms Decry Clinical Trial Provisions In Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
Digital mammography systems are on the verge of being downclassified to 510(k) status, but imaging firms say the clinical trial requirements proposed in FDA's draft "special controls" guidance for the systems are costly, unnecessary and overly burdensome
You may also be interested in...
Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule
Two-dimensional digital mammography systems, such as those made by Hologic and GE Healthcare, can now enter the market through the 510(k) versus PMA route, according to a final rule and special controls guidance issued Nov. 4.
Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule
Two-dimensional digital mammography systems, such as those made by Hologic and GE Healthcare, can now enter the market through the 510(k) versus PMA route, according to a final rule and special controls guidance issued Nov. 4.
Clinical Data Needed For Some Digital Mammography 510(k)s, Panel Says
FDA should require some clinical data in 510(k) or de novo 510(k) submissions for new full-field digital mammography devices that substantially change or improve the perception of breast cancer images when compared with prior models, an FDA advisory panel recommended Nov. 17